What's Happening?
Orsini, a leader in rare disease pharmacy solutions, has been announced as the single-source specialty pharmacy partner for Glaukos' Epioxa, a novel therapy for keratoconus. Epioxa, approved by the FDA in October 2025, offers an incision-free alternative
to traditional corneal cross-linking procedures, reducing pain and recovery time while delivering clinically meaningful outcomes. Keratoconus is a progressive eye disease that thins the cornea, leading to distorted vision and potentially requiring corneal transplants. Orsini's partnership with Glaukos aims to expand access to this innovative treatment, improving outcomes for patients with keratoconus.
Why It's Important?
The partnership between Orsini and Glaukos is crucial as it provides patients with keratoconus access to a groundbreaking treatment that simplifies the procedure and minimizes recovery time. Epioxa's approval and distribution through Orsini represent a significant advancement in keratoconus care, offering a less invasive option that could improve the quality of life for patients. This collaboration highlights the importance of specialty pharmacy solutions in delivering cutting-edge therapies for rare diseases, ensuring that patients receive comprehensive and compassionate care. The partnership also underscores the role of innovative treatments in addressing unmet medical needs and improving healthcare outcomes.
